Go Pro
→ AI Just Found a Hole in America's Banks (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
$0.02
$0.00
▼
$0.23
N/AN/A64,362 shs2,314 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMAW
Humacyte
$0.01
+7.5%		$0.02
$0.00
▼
$0.50
N/AN/A20,753 shs1,357 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%+15.46%-42.27%-88.18%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%+30.94%+31.88%+9.64%-28.06%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Humacyte, Inc. stock logo
HUMAW
Humacyte
0.00%-14.00%-14.00%-88.09%-98.13%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
$0.02
$0.00
▼
$0.23
N/AN/A64,362 shs2,314 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMAW
Humacyte
$0.01
+7.5%		$0.02
$0.00
▼
$0.50
N/AN/A20,753 shs1,357 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%+15.46%-42.27%-88.18%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%+30.94%+31.88%+9.64%-28.06%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Humacyte, Inc. stock logo
HUMAW
Humacyte
0.00%-14.00%-14.00%-88.09%-98.13%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
Humacyte, Inc. stock logo
HUMAW
Humacyte
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$559.42MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMAW
Humacyte
$2.02MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMAW
Humacyte
N/AN/AN/AN/AN/AN/AN/AN/A8/17/2026 (Estimated)

Latest HUMAW, ALVOW, APLMW, and ARAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Alvotech stock logo
ALVOW
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
8/17/2026N/A
Humacyte, Inc. stock logo
HUMAW
Humacyte
-$0.0980N/AN/AN/A$1.12 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMAW
Humacyte
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
Humacyte, Inc. stock logo
HUMAW
Humacyte
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
Humacyte, Inc. stock logo
HUMAW
Humacyte
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
Humacyte, Inc. stock logo
HUMAW
Humacyte
150N/AN/ANot Optionable

Recent News About These Companies

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
August 7 at 6:52 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/humacyte-to-announce-2026-second-quarter-financial-results-and-provide-business-update-on-august-12-2026-1036428363
Humacyte to begin testing bioengineered blood vessel in heart bypass surgery
July 28, 2026  |  ncbiotech.orgN
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual ...
June 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-care-for-women-on-dialysis-in-phase-3-results-presented-at-the-society-for-vascular-surgery-vascular-annual-meeting-1036249157
Biggest stock movers: ORCL, HUMA, and more
June 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4602464-biggest-stock-movers-orcl-huma-and-more
Humacyte prices $50M public offering of common stock at $1.05/share
June 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/humacyte-prices-50m-public-offering-of-common-stock-at-1-05-share/ar-AA25m1jH
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses
June 10, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/huma-stock-plunges-after-hours-on-proposed-share-offering-even-as-dialysis-data-impresses/ar-AA25kRdW
Humacyte (HUMA) Q1 2025 Earnings Transcript
June 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/humacyte-huma-q1-2025-earnings-143843507.html
Humacyte, Inc: Humacyte Appoints Jim Mercadante as Chief Commercial Officer
April 22, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68268435-humacyte-inc-humacyte-appoints-jim-mercadante-as-chief-commercial-officer-399.htm
Humacyte (HUMA) price target decreased by 31.82% to 5.46
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/humacyte-huma-price-target-decreased-by-3182-to-546/ar-AA20v5u6
Benchmark downgrades Humacyte (HUMA)
April 1, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/benchmark-downgrades-humacyte-huma/ar-AA1ZSyVO
Why BTIG cut its target on Humacyte (HUMA) but kept a bullish view on the bigger opportunity
March 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/why-btig-cut-its-target-on-humacyte-huma-but-kept-a-bullish-view-on-the-bigger-opportunity/ar-AA1ZG63i
Humacyte, Inc: Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68059393-humacyte-inc-humacyte-announces-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-399.htm
Humacyte misses revenue target despite in-line earnings
March 27, 2026  |  investing.comhttps://www.investing.com/news/earnings/humacyte-misses-revenue-target-despite-inline-earnings-93CH-4584672
Is Humacyte (HUMA) Using Middle East Partnerships To Reframe Its Capital and Market Access Strategy?
March 24, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/humacyte-huma-using-middle-east-030814812.html
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess
March 20, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/humacyte-inc-huma-submits-marketing-authorization-application-in-israel-for-symvess/ar-AA1Z3be9
Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today?
March 19, 2026  |  msn.comhttps://www.msn.com/en-us/money/markets/humacyte-secures-15m-saudi-order-why-did-huma-stock-crash-to-record-low-today/ar-AA1YZMHV
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
March 19, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/humacyte-receives-symvess-purchase-commitment-for-clinical-evaluation-and-outreach-program-in-the-kingdom-of-saudi-arabia-1035945566
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential
February 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/humacyte-huma-valuation-check-dod-081043142.html
D Boral Capital maintains Humacyte (HUMA) buy recommendation
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/d-boral-capital-maintains-humacyte-huma-buy-recommendation/ar-AA1SSaeG
Humacyte announces long-term safety, efficacy results of Symvess
December 22, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/humacyte-announces-long-term-safety-efficacy-results-of-symvess/ar-AA1SQe7q

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)
As of 08/7/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.02 0.00 (0.00%)
As of 08/7/2026 03:41 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 08/7/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Humacyte stock logo

Humacyte NASDAQ:HUMAW

$0.0086 +0.00 (+7.50%)
As of 08/7/2026 11:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas